In yesterday’s Wall Street session, DICE Therapeutics Inc. (NASDAQ:DICE) shares traded at $47.45, up 0.15% from the previous session.
9 analysts cover DICE Therapeutics Inc. (NASDAQ:DICE), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $48.00 and a low of $48.00, we find $48.00. Given the previous closing price of $47.38, this indicates a potential upside of 1.31 percent. DICE stock price is now 14.43% away from the 50-day moving average and 39.31% away from the 200-day moving average. The market capitalization of the company currently stands at $2.26B.
The stock has received a hold rating from 9 analysts and a buy rating from 0. Brokers who have rated the stock have averaged $48.00 as their price target over the next twelve months.
With the price target of $38, Wells Fargo recently initiated with Equal Weight rating for DICE Therapeutics Inc. (NASDAQ: DICE).
In other news, Northpond Ventures GP, LLC, 10% Owner sold 2,492,871 shares of the company’s stock on Jun 22. The stock was sold for $115,918,502 at an average price of $46.50. Upon completion of the transaction, the 10% Owner now directly owns 166,293 shares in the company, valued at $7.89 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 01, CSO Jacobsen John R. sold 18,750 shares of the business’s stock. A total of $572,444 was realized by selling the stock at an average price of $30.53. This leaves the insider owning 147,497 shares of the company worth $7.0 million. Insiders disposed of 211,996 shares of company stock worth roughly $10.06 million over the past 1 year. A total of 3.16% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DICE stock. A new stake in DICE Therapeutics Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $65,291,000. NICHOLAS INVESTMENT PARTNERS, LP invested $19,746,000 in shares of DICE during the first quarter. In the first quarter, PICTON MAHONEY ASSET MANAGEMENT acquired a new stake in DICE Therapeutics Inc. valued at approximately $17,557,000. SEGANTII CAPITAL MANAGEMENT LTD acquired a new stake in DICE for approximately $9,490,000. SCHONFELD STRATEGIC ADVISORS LLC purchased a new stake in DICE valued at around $1,880,000 in the second quarter. In total, there are 191 active investors with 79.20% ownership of the company’s stock.
On Thursday morning DICE Therapeutics Inc. (NASDAQ: DICE) stock kicked off with the opening price of $47.52. During the past 12 months, DICE Therapeutics Inc. has had a low of $15.08 and a high of $47.90. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 32.40, and a quick ratio of 32.40. The fifty day moving average price for DICE is $41.72 and a two-hundred day moving average price translates $34.11 for the stock.
The latest earnings results from DICE Therapeutics Inc. (NASDAQ: DICE) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.54, beating analysts’ expectations of -$0.58 by 0.04. This compares to -$0.50 EPS in the same period last year. The company reported revenue of $31.57 million for the quarter, compared to $18.86 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 67.44 percent.
DICE Therapeutics Inc.(DICE) Company Profile
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company’s lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.
